Literature DB >> 8688333

P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.

R Dahiya1, G Deng, K M Chen, R M Chui, P C Haughney, P Narayan.   

Abstract

Mutations in the p53 tumour-suppressor gene are among the most common genetic alterations in human cancers. In the present study we analysed the mutations in the p53 tumor-suppressor gene in 25 primary and 20 metastatic human prostate cancer specimens. DNA extracted from the paraffin-embedded sections was amplified by hot-start polymerase chain reaction, and p53 gene mutations in the conserved mid-region (exons 4-9) were examined using single-strand conformation polymorphism (SSCP) analysis and immunohistochemistry. In the present study, we used a novel hot-start PCR-SSCP technique using DNA Taq polymerase antibody, which eliminates primer-dimers and non-specific products. Because of this new technique, the results of PCR-SSCP showed very high resolution. Polymerase chain reaction products were sequenced directly for point mutations for the p53 gene. Mutations were found in 2 out of 25 primary prostate cancers (8%) and 4 out of 20 metastatic cancers (20%). Mutations were observed exclusively in exon 7 and not in exons 4, 5, 6, 8 or 9. Nuclear accumulation of p53 protein, determined by immunohistochemistry, correlated with the degree of metastasis in prostatic cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8688333      PMCID: PMC2074577          DOI: 10.1038/bjc.1996.349

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  Genetic mechanisms of tumor suppression by the human p53 gene.

Authors:  P L Chen; Y M Chen; R Bookstein; W H Lee
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

2.  Olfactory recognition: a simple memory system.

Authors:  P Brennan; H Kaba; E B Keverne
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

3.  Identification of a p53-dependent negative response element in the bcl-2 gene.

Authors:  T Miyashita; M Harigai; M Hanada; J C Reed
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

Review 4.  Clinical implications of the p53 tumor-suppressor gene.

Authors:  C C Harris; M Hollstein
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

5.  Wild-type p53 can inhibit oncogene-mediated focus formation.

Authors:  D Eliyahu; D Michalovitz; S Eliyahu; O Pinhasi-Kimhi; M Oren
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

6.  P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia.

Authors:  S J Thompson; K Mellon; R G Charlton; C Marsh; M Robinson; D E Neal
Journal:  Br J Urol       Date:  1992-06

Review 7.  Oncogenes in prostate cancer. An update.

Authors:  D M Peehl
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860

8.  Mutant p53 expression in prostate carcinoma.

Authors:  P J Van Veldhuizen; R Sadasivan; F Garcia; M S Austenfeld; R L Stephens
Journal:  Prostate       Date:  1993       Impact factor: 4.104

9.  p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.

Authors:  V Dulić; W K Kaufmann; S J Wilson; T D Tlsty; E Lees; J W Harper; S J Elledge; S I Reed
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

10.  Regression of LNCaP human prostate tumor xenografts in athymic nude mice by 13-cis-retinoic acid and androgen ablation.

Authors:  R Dahiya; D Y Zhang; R J Ho; P C Haughney; S W Hayward; G R Cunha; P Narayan
Journal:  Biochem Mol Biol Int       Date:  1995-03
View more
  1 in total

1.  Magnifying chromoendoscopy combined with immunohistochemical staining for early diagnosis of gastric cancer.

Authors:  Xian-Mei Meng; Yi Zhou; Tong Dang; Xu-Yang Tian; Jie Kong
Journal:  World J Gastroenterol       Date:  2013-01-21       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.